Since thrombolytic efficacy is currently limited by dose dependent ICH (requiring tPA dose to be restricted to 0.9 mg/Kg), a thrombolytic with a selective antidote for ICH would not have this limitation and could improve thrombolytic efficacy in stroke to an unprecedented degree. This evidence concerns the gene PLAT and stroke disorder.